- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
Awarded by Hasso Plattner Ventures, Deutsche Bank, Deutsche Telekom and MAN Ferrostaal
Berlin, June 30th, 2009 – Cytolon AG announced today that Founder and Chief Executive Officer Thomas Klein received the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD" at the 5th Hasso Plattner Ventures Forum on Entrepreneurship. The award was presented by Eran Davidson, President and CEO of Hasso Plattner Ventures, Dr. Joseph Ackermann, CEO of Deutsche Bank, Dr. Klaus Lesker, Member of the Executive Board of MAN Ferrostaal and Mr. Heinrich Arnold, Member of the Executive Board of Deutsche Telekom. Mr. Klein cordially thanked the presenters stating "The team at Cytolon is extremely pleased and proud to receive this award from the Hasso Plattner Ventures Forum on Entrepreneurship. Our entrepreneurial thrust stems from the exciting technology of adult stem cell-based diagnostics and therapeutics. We are fortunate to be in the midst of current developments in this industry and able to provide significant services for patients, clinics, stem cells banks and other industry participants". The Hasso Plattner Ventures Forum indicated that Cytolon AG is the first company to establish a matching and brokering platform for adult stem cell products. Cytolon links patients, clinics, stem cell banks and pharmaceutical and biotechnology companies intimately in using adult stem cell products and services. Mr. Davidson stated "We have selected Cytolon for this award as it is the first company with cutting edge services for the regenerative medicine market; services that will save lives". About Cytolon AG: Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell area. For more information, please visit the company's Web site at www.cytolon.com.
Contact:
Nina Hofle - PR Manager
Cytolon AG
Am Karlsbad 15
10785 Berlin - Germany
phone: +49 (0) 30 2639 288-0
fax: +49 (0) 30 2639 288-20
e-mail: info@cytolon.com
web: www.cytolon.com